TY - JOUR
T1 - The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
AU - For the Paediatric Rheumatology International Trials Organisation (PRINTO)
AU - Al-Abrawi, Safiya
AU - Al-Mayouf, Sulaiman M.
AU - Abdwani, Reem
AU - Abdalla, Eiman Ibrahim Abdel Aziz
AU - Consolaro, Alessandro
AU - Bovis, Francesca
AU - Ruperto, Nicolino
N1 - Funding Information:
Funding This study was funded and coordinated by Istituto Giannina Gaslini, Genoa, Italy.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/4/1
Y1 - 2018/4/1
N2 - The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Omani Arabic language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 57 JIA patients (22.8% systemic, 28.1% oligoarticular, 35.1% RF negative polyarthritis, 14.0% other categories) and 85 healthy children, were enrolled in two centres. Notably, none of the enrolled JIA patients is affected with enthesitis-related arthritis or undifferentiated arthritis. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. In conclusion, the Omani Arabic version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
AB - The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Omani Arabic language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 57 JIA patients (22.8% systemic, 28.1% oligoarticular, 35.1% RF negative polyarthritis, 14.0% other categories) and 85 healthy children, were enrolled in two centres. Notably, none of the enrolled JIA patients is affected with enthesitis-related arthritis or undifferentiated arthritis. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. In conclusion, the Omani Arabic version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
KW - Disease status
KW - Functional ability
KW - Health related quality of life
KW - JAMAR
KW - Juvenile idiopathic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85045253860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045253860&partnerID=8YFLogxK
U2 - 10.1007/s00296-018-3965-9
DO - 10.1007/s00296-018-3965-9
M3 - Article
C2 - 29637367
AN - SCOPUS:85045253860
SN - 0172-8172
VL - 38
SP - 299
EP - 306
JO - Rheumatology International
JF - Rheumatology International
ER -